Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain.

A M Alonso TorresA G Arévalo BernabéN Becerril Ríos María Fuensanta Hellín Gil José Manuel Martinez Sesmero Virginia Meca-Lallana Lluis Ramio-Torrentà Alfredo Rodríguez-Antigüedad L Gómez MaldonadoI Triana JuncoM Gómez-Barrera Nataly Espinoza-Cámac Itziar Oyagüez

Published in: PharmacoEconomics - open (2023)

Besides the potential benefits of convenient administration and improving work-life balance, as suggested by the expert panel, natalizumab SC was associated with cost savings for the healthcare system by avoiding drug preparation, reducing administration time, and freeing up infusion suite capacity. Additional cost savings could be derived with regional hospital administration of natalizumab SC by reducing productivity loss.

Keyphrases

multiple sclerosis
white matter
healthcare
low dose
climate change
emergency department
adverse drug
risk assessment
mass spectrometry
high resolution
drug induced